Opportunities
HelixForge Therapeutics
DiscoverActiveEMEAHybrid
Genomic analysis turnaround & dataset growth
€450.0K
17
0
0
0
0
Industry
Healthcare & Life Sciences
Country / Region
Switzerland / EMEA
Close Date
—
Sales Owner
—
SE Owner
—
Probability (SE judgement)
30%
Quote Status
—
Contract Value
€900.0K
Critical qualification gaps
Economic Buyer (Unknown)Champion (Unknown)Decision Criteria (Weak)Decision Process (Unknown)
Next Action
Complete data-path investigation workshop
Owner: Marco Rossi · Due: 2026-12-15
Business Challenge & Consequences
Genomic analysis turnaround growing with dataset size; data path not yet characterised.
Slower discovery cycles; analysis backlog.
Desired Business Outcomes
Faster genomic pipeline turnaround; predictable performance as data grows.
Compelling Event
Sequencing capacity expansion planned
Workloads & Solution Direction
Research/genomics pipelinesAnalytics and data engineering
Primary Direction
inference-context
Application / Framework
—
Current Environment
Compute / GPU
Mixed CPU + 8× A100
GPU / Node Counts
8× A100
Storage / Data Platform
NFS + object store
Network
100Gb Ethernet
Workload Characteristics
Data Capacity & Growth
—
Active Working Set
20 TB
Current Performance
48h per pipeline batch
Target Performance
24h per pipeline batch
Access Patterns
Mixed file/object, metadata-light
Read/Write, Concurrency
—
Required Protocols
NFS, S3
Checkpoint / Restart
—
Availability / Recovery
—
Security / Residency
—
Known Technical Blockers
Data path bottleneck not yet isolated
Success Criteria (agreed)
Not yet agreed
Competition & Alternatives
Competitors
Cloud object storage
Alternatives
Expand NFS, do nothing
